Literature DB >> 19335126

Pial synangiosis in patients with moyamoya syndrome and sickle cell anemia: perioperative management and surgical outcome.

Edward R Smith1, Craig D McClain, Matthew Heeney, R Michael Scott.   

Abstract

OBJECT: Many children with sickle cell anemia (SCA) also have clinical and radiographic findings of an arteriopathy suggestive of moyamoya syndrome. These patients may continue to experience strokes despite optimal medical management. The authors wished to define features of moyamoya syndrome associated with SCA and determine the results of surgical revascularization in these patients at early and late follow-up.
METHODS: The authors reviewed the clinical and radiographic records of all patients with moyamoya syndrome and SCA who underwent cerebral revascularization surgery using a standardized surgical procedure-pial synangiosis-from 1985 to 2008.
RESULTS: Twelve patients had SCA and moyamoya syndrome. Six patients were female and 6 were male. The average patient age at surgery was 11.3 years (range 3-22 years). All patients presented with ischemic symptoms, 11 (92%) with previous transient ischemic attacks, and 10 (83%) with completed strokes. Eleven patients (92%) had radiographic evidence of previous stroke at presentation. None presented with hemorrhage. Surgical treatment included pial synangiosis in all patients. Complications included 1 perioperative stroke, 1 wound infection, and 1 perioperative pneumonia. The average length of hospital stay was 5.7 days (including a 24-hour preoperative admission for hydration) and average blood loss was 92.5 ml/hemisphere (in a total of 19 hemispheres). Clinical and radiographic follow-up with an average of 49 months (range 9-144 months) demonstrated no worsening in neurological status in any patient. No clinical or radiographic evidence of new infarcts was observed in any patient at late follow-up, despite disease progression in 13 (68%) of 19 hemispheres.
CONCLUSIONS: The clinical and radiographic features of moyamoya syndrome associated with SCA appear comparable to primary moyamoya disease. Successful treatment of these patients requires multidisciplinary care involving hematologists, anesthesiologists, and neurosurgeons. Operative treatment of moyamoya syndrome using pial synangiosis appears to be safe and confers long-lasting protection against further stroke in this population, and provides an alternative for failure of optimal medical therapy in patients. This study underscores the potential merit of screening patients with SCA for moyamoya syndrome.

Entities:  

Mesh:

Year:  2009        PMID: 19335126     DOI: 10.3171/2009.01.FOCUS08307

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  17 in total

Review 1.  The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease.

Authors:  John J Strouse; Sophie Lanzkron; Victor Urrutia
Journal:  Expert Rev Hematol       Date:  2011-12       Impact factor: 2.929

Review 2.  Concurrent Graves' disease and intracranial arterial stenosis/occlusion: special considerations regarding the state of thyroid function, etiology, and treatment.

Authors:  Shigeo Ohba; Toru Nakagawa; Hideki Murakami
Journal:  Neurosurg Rev       Date:  2011-03-19       Impact factor: 3.042

3.  When and why is surgical revascularization indicated for the treatment of moyamoya syndrome in patients with RASopathies? A systematic review of the literature and a single institute experience.

Authors:  Marcello Scala; Pietro Fiaschi; Valeria Capra; Maria Luisa Garrè; Domenico Tortora; Marcello Ravegnani; Marco Pavanello
Journal:  Childs Nerv Syst       Date:  2018-05-24       Impact factor: 1.475

4.  Reduction in Overt and Silent Stroke Recurrence Rate Following Cerebral Revascularization Surgery in Children with Sickle Cell Disease and Severe Cerebral Vasculopathy.

Authors:  Erin M Hall; Jeffrey Leonard; Jodi L Smith; Kristin P Guilliams; Michael Binkley; Robert J Fallon; Monica L Hulbert
Journal:  Pediatr Blood Cancer       Date:  2016-04-22       Impact factor: 3.167

5.  Moyamoya syndrome associated with Graves' disease: a case series study.

Authors:  Jun Ni; Li-Xin Zhou; Yan-Ping Wei; Ming-Li Li; Wei-Hai Xu; Shan Gao; Li-Ying Cui
Journal:  Ann Transl Med       Date:  2014-08

Review 6.  Neurologic Complications of Sickle Cell Disease.

Authors:  Shama Farooq; Fernando D Testai
Journal:  Curr Neurol Neurosci Rep       Date:  2019-02-28       Impact factor: 5.081

7.  Moyamoya syndrome in sickle cell anaemia: a cause of recurrent stroke.

Authors:  Deanne Soares; Richard Bullock; Susanna Ali
Journal:  BMJ Case Rep       Date:  2014-09-01

Review 8.  Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.

Authors:  Samir K Ballas; Muge R Kesen; Morton F Goldberg; Gerard A Lutty; Carlton Dampier; Ifeyinwa Osunkwo; Winfred C Wang; Carolyn Hoppe; Ward Hagar; Deepika S Darbari; Punam Malik
Journal:  ScientificWorldJournal       Date:  2012-08-01

9.  Cerebrovascular autoregulation in pediatric moyamoya disease.

Authors:  Jennifer K Lee; Monica Williams; Jacky M Jennings; Jessica L Jamrogowicz; Abby C Larson; Lori C Jordan; Eugenie S Heitmiller; Charles W Hogue; Edward S Ahn
Journal:  Paediatr Anaesth       Date:  2013-03-18       Impact factor: 2.556

10.  Moyamoya arteriopathy.

Authors:  Edward R Smith
Journal:  Curr Treat Options Neurol       Date:  2012-12       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.